• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BHVN

    Biohaven Ltd.

    Subscribe to $BHVN
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

    IPO Year: 2022

    Exchange: NYSE

    Website: biohavenpharma.com

    Peers

    $RPRX

    Recent Analyst Ratings for Biohaven Ltd.

    DatePrice TargetRatingAnalyst
    2/11/2025$65.00Buy
    Deutsche Bank
    9/16/2024$57.00Buy
    Jefferies
    9/4/2024$55.00Outperform
    Bernstein
    7/24/2024$58.00Overweight
    Morgan Stanley
    2/16/2024$62.00Outperform
    RBC Capital Mkts
    2/6/2024$59.00Buy
    UBS
    12/22/2023$50.00Buy
    H.C. Wainwright
    12/8/2023$58.00Outperform
    Robert W. Baird
    1/24/2023$24.00Outperform
    SVB Securities
    1/4/2023$23.00Overweight
    JP Morgan
    See more ratings

    Biohaven Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biohaven Announces Investment up to $600 Million by Oberland Capital

      Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales$250 million to be funded at closing$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expensesNEW HAVEN, Conn., April 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseas

      4/28/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

      SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer

      4/5/25 9:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

      Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn-targeting competition.Up to 84% reduction of total IgG was observed with a median reduction of 80% after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Subcutaneous BHV-1300 achieved progressive reductions in IgG levels within hours of each weekly dose administration, and pharmacodynamic effects were sustained compared to baseline over the four-week period.Dose escalation with BHV-1300 continues in the study and plans to explore deeper reductions to characterize the potential r

      3/3/25 7:31:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

      Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025.Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million.Reported positive degrader data with multiple doses of BHV-1300 achieving up to 84% reduction of total IgG, with a median reduction of 80%, after subcutaneous weekly 1000 mg dosing in the ongoing Phase 1 study.Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differ

      3/3/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

      Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the primary and secondary outcome measures at the 3-year endpoint in a real-world evidence (RWE) study.Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025.NEW HAVEN, Conn., Feb. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) ha

      2/11/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy

      Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas.Announces multiple advancements across the MoDETM (molecular degraders of extracellular proteins) platform and the next generation TRAPTM (targeted removal of aberrant protein) degraders, including:IgA Nephropathy (IgAN) program: First-in-human dosing with BHV-1400, a next generation TRAP degrader, achieved rapi­d, deep, and selective lowering of only aberrant galactose-deficient IgA1 (Gd-IgA1), the antibody causing IgA nephropathy, while sparing normal IgA.This selective and rapid approach to immunoglobulin lowering represents a second-generation therapeutic approach to IgAN, pot

      1/13/25 11:15:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

      NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE:BHVN) and Merus N.V. (NASDAQ:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies. Under the terms of the agreement, Biohaven is responsible for the preclinical ADC generation of three Merus bispecific antibodies under mutually agreed research plans. The agreement includes two Merus bispecific programs generated using the Biclonics® platform, and

      1/12/25 8:04:12 PM ET
      $BHVN
      $MRUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      NEW HAVEN, Conn., Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 13, 2025, at 8:15 am (PT). About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative p

      1/7/25 5:54:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

      BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD.Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within hours of each weekly dose administration, and pharmacodynamic effects were sustained relative to baseline over the four-week period. The optimized subcutaneous formulation also showed substantially less inter-patient variability in the MAD compared to the previously reported intravenously administered BHV-1300.BHV-1300 has been safe and well tolerated across the ongoing Phase 1 without any dose limiting toxicity to date. All AEs have been mild, with no SAEs or discontinuations related to study drug

      12/16/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biohaven Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Biohaven Ltd. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Biohaven Ltd. SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/14/24 3:06:46 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/12/24 1:20:24 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/4/24 11:16:33 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      6/10/22 2:57:01 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      6/10/22 8:41:37 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      5/10/22 11:56:34 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      2/11/22 2:48:54 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      2/11/22 11:19:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

      SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      2/3/22 4:41:26 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)

      2/16/21 2:04:34 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $996,238 worth of shares (32,700 units at $30.47) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 7:01:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Childs John W bought $2,999,970 worth of shares (73,170 units at $41.00) (SEC Form 4)

      4/A - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 6:59:47 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $1,042,393 worth of shares (29,000 units at $35.94) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      12/31/24 7:00:14 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $999,970 worth of shares (21,052 units at $47.50) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      10/3/24 7:01:22 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Coric Vlad bought $999,970 worth of shares (21,052 units at $47.50) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      10/3/24 7:00:38 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bailey Gregory bought $220,966 worth of shares (5,000 units at $44.19), increasing direct ownership by 0.31% to 1,620,071 units (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      9/25/24 7:30:20 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $1,012,983 worth of shares (28,400 units at $35.67) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      7/19/24 8:56:50 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Car Bruce bought $1,007,490 worth of shares (30,000 units at $33.58) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      6/20/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Childs John W bought $996,240 worth of shares (28,000 units at $35.58) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/31/24 9:04:05 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bailey Gregory bought $512,877 worth of shares (15,000 units at $34.19), increasing direct ownership by 0.94% to 1,615,071 units (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/15/24 7:31:29 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Biohaven Ltd. (0001935979) (Filer)

      5/7/25 5:18:11 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      4/28/25 7:59:17 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Biohaven Ltd.

      DEFA14A - Biohaven Ltd. (0001935979) (Filer)

      3/18/25 4:48:49 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Biohaven Ltd.

      DEF 14A - Biohaven Ltd. (0001935979) (Filer)

      3/18/25 4:47:10 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      3/3/25 4:26:30 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Biohaven Ltd.

      10-K - Biohaven Ltd. (0001935979) (Filer)

      3/3/25 4:25:21 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Biohaven Ltd.

      SCHEDULE 13G/A - Biohaven Ltd. (0001935979) (Subject)

      2/14/25 12:23:05 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      1/13/25 11:16:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      11/12/24 4:16:05 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Biohaven Ltd.

      10-Q - Biohaven Ltd. (0001935979) (Filer)

      11/12/24 4:11:56 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biohaven Ltd. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Antonijevic Irina

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:16:02 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heffernan Michael Thomas

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:15:04 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:14:32 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mehta Kishan

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:13:54 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gregory Julia P

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:13:14 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Childs John W

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:12:36 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hugin Robert J

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:11:58 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $996,238 worth of shares (32,700 units at $30.47) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 7:01:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Childs John W bought $2,999,970 worth of shares (73,170 units at $41.00) (SEC Form 4)

      4/A - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 6:59:47 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Car Bruce converted options into 4,750 shares and covered exercise/tax liability with 2,331 shares, increasing direct ownership by 102% to 4,802 units (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      1/7/25 8:51:26 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biohaven Ltd. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Biohaven with a new price target

      Deutsche Bank initiated coverage of Biohaven with a rating of Buy and set a new price target of $65.00

      2/11/25 7:01:45 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Biohaven with a new price target

      Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00

      9/16/24 7:22:04 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on Biohaven with a new price target

      Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00

      9/4/24 7:31:23 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Biohaven with a new price target

      Morgan Stanley initiated coverage of Biohaven with a rating of Overweight and set a new price target of $58.00

      7/24/24 6:21:29 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Biohaven with a new price target

      RBC Capital Mkts initiated coverage of Biohaven with a rating of Outperform and set a new price target of $62.00

      2/16/24 7:22:26 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Biohaven with a new price target

      UBS initiated coverage of Biohaven with a rating of Buy and set a new price target of $59.00

      2/6/24 6:22:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Biohaven with a new price target

      H.C. Wainwright initiated coverage of Biohaven with a rating of Buy and set a new price target of $50.00

      12/22/23 7:21:17 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Biohaven with a new price target

      Robert W. Baird initiated coverage of Biohaven with a rating of Outperform and set a new price target of $58.00

      12/8/23 8:45:58 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on Biohaven with a new price target

      SVB Securities initiated coverage of Biohaven with a rating of Outperform and set a new price target of $24.00

      1/24/23 7:23:06 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Biohaven with a new price target

      JP Morgan initiated coverage of Biohaven with a rating of Overweight and set a new price target of $23.00

      1/4/23 7:22:03 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biohaven Ltd. Financials

    Live finance-specific insights

    See more
    • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

      Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

      9/23/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

      Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

      9/20/24 7:09:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

      Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

      3/22/23 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

      Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS(2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS(3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer Fourth-Quarter 2022 Reported Diluted EPS(2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS(3) of $1.14, Up 45% Year-Over-Y

      1/31/23 6:45:00 AM ET
      $BHVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

      Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the Current Period Related to Tax Resolutions for Multiple Years Impacting Both Reported(2) and Adjusted(3) Diluted EPS Third-Quarter 2022 Adjusted Diluted EPS(3) of $1.78, Reflecting 40% Growth Over Third-Quarter 2021; Excluding Foreign Exchange Impacts, Adjusted Diluted EPS(3) Grew 44% Raises Lower

      11/1/22 6:45:00 AM ET
      $BHVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments

      Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SECNURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57%Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per shareFeatured 31 new and encore presen

      8/5/22 7:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer to Acquire Biohaven Pharmaceuticals

      Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer's innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus 0.5 of a share of a new publicly traded company that retains Biohaven's non-CGRP pipeline compounds ("New Biohaven") Pfizer and Biohaven to hold analyst call at 10am ET today Pfizer Inc. (NYSE:PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced that the companies have entered into a definitive agreement under which Pfi

      5/10/22 6:45:00 AM ET
      $BHVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022

      NEW HAVEN, Conn., May 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended March 31, 2022, and provide a review of recent accomplishments and anticipated upcoming milestones, on Wednesday, May 11, 2022 at 8:30 a.m. ET.   The earnings call and webcast will follow Biohaven's issuance of its first quarter 2022 earnings release and the filing of its quarterly report on Form 10-Q for the

      5/9/22 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS

      NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones. Vlad Coric, M.D., Chief Executive Officer and Chairman of the Board of Biohaven commented, "Last year was transformative for Biohaven as NURTE

      2/25/22 7:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences

      NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN, the ", Company", or ", Biohaven", ))) announced today that it has entered into a definitive agreement to acquire Channel Biosciences, LLC, a subsidiary of Knopp Biosciences LLC, and its Kv7 channel targeting platform – adding the latest advances in ion-channel modulation to Biohaven's growing neuroscience portfolio. The Kv7 platform has been developed and refined for over a decade by a team with deep experience in ion channel science led by Michael Bozik, M.D., and Steven Dworetzky, Ph.D. Both leaders, along with members of their scientific team, are anticipated to join Biohaven as part o

      2/25/22 6:55:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Biohaven Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

      Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

      5/12/23 4:30:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy

      NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.   Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K

      4/17/23 7:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer

      NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also announced the appointment of Matthew Buten to the role of Chief Financial Officer (CFO) effective by December 20, 2021, following the retirement of CFO James Engelhart. Both Dr. Doogan and Mr. Engelhart will continue

      12/6/21 7:29:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilgamesh Builds Team of Pharmaceutical Industry Leaders and Appoints New Members to Board of Directors

      NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a mental health focused biotechnology company developing novel psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the addition of several key additions to its leadership team and board of directors. The additions will enable Gilgamesh to rapidly advance its pipeline toward clinical trials beginning in late 2022 and further expand its IP portfolio. Key hires include: Chief Medical Officer Gerard Marek, MD/Ph.D. is a renowned expert on serotonin system biology. Gerard is a former asst. professor at Yale University and was the Chief Scientific Officer of Psychiatric Disorders Discove

      11/11/21 9:00:00 AM ET
      $BHVN
      $SWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Biohaven Appoints Kishen Mehta to Board of Directors

      NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board"). Mr. Mehta previously served as a strategic advisor to Biohaven. Declan Doogan, M.D., Chairman of Biohaven's Board of Directors, commented, "We are excited to welcome Kishen to Biohaven's Board of Directors and have access to his impressive business and financial acumen to help us continue to excel in achieving our goal of becoming a l

      6/17/21 4:01:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care